Substitute for Form 1449 A & B/PTO



INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

olete if Known					
Application Number	10/517,137				
Confirmation Number	6831				
Filing Date	December 07, 2004				
First Named Inventor	Rian VAN MEETEREN				
Art Unit	-Unknown 1614				
Examiner Name	LESUE A, ROYDS				
Attorney Docket Number	Q84960				

	U.S. PATENT DOCUMENTS						
Examiner	Cite No.1	Document Number		Publication Date			
Initials*		Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		US					

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
NAC		EP	801 067	A1	10-15-1997	Yamanouchi Pharmaceutical Co., Ltd.	
LAR		wo	96/38143	A1	12-05-1996	Synaptic Pharmaceutical Corp.	
LAR		WO	99/57131 -	A1	11-11-1999	Duke University	7
LAIL		EP	34 432	A2	08-26-1981	Yamanouchi Pharmaceutical Co. Ltd.	7
LAL		EP	1 088 551	Al	04-04-2001	Yamanouchi Pharmaceutical Co. Ltd	7
LAL		EP	1 203 582	Al	05-08-2002	Yamanouchi Pharmaceutical Co. Ltd.	V .

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
LAR		SELLERS, Donna J. et al, "Potential therapeutic targets for the treatment of the overactive bladder", World Journal of Urology, vol. 19, no. 5, p307-311, 2001	
AR		SCARPA, R.M. "Lower Urinary tract symptoms: what are implications for the patients?" European Urology, vol. 40, suppl. 4, p12-20, 2001	
LAYL		Current Therapy, vol. 19, no. 12, p8-11, 2001, with English translation	
LAR		Urology, vol. 55, suppl. 5a, p1-2, 2000 +	/
LAL		Medicines and Drug Journal, vol. 38, S-1, p283-288, 2002, with English translation	/
LP9-		BJU International, vol. 85, suppl. 2, p6-11, 2000	
LINL		Shinyaku-to-Rinsho, vol. 44, no. 8, p61-64, 1995, with English translation	
LAY		BJU International, vol. 85, Suppl. 2, p25-30, 2000	7
LAL		Neurology and Urodynamics, vol. 17, No. 1, p31-36, 1998 •	7
LAN		European Urology, vol. 36, Suppl. 1, p89-95, 1999 •	17
LAL		European Urology Supplements, 2, No. 1, p171, 674, 2003	17
LAY		Japan Pharmaceutical Reference, Products and Administration in Japan, The Fifth Edition (1999), p1263- 1265	/
IAC		AHFS Drug Information 2000, p§712-3713	V

Examiner Signature Date Considered 07 DECEMBER 2005

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.